Ignite Creation Date:
2024-05-06 @ 5:44 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05418166
Status:
UNKNOWN
Last Update Posted:
2022-06-14
First Post:
2022-06-05
Brief Title:
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
Sponsor:
First Affiliated Hospital of Harbin Medical University
Organization:
First Affiliated Hospital of Harbin Medical University
Study Overview
Official Title:
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EvoACS
Brief Summary:
The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome ACS while on Ticagrelor and Aspirin treatment
Detailed Description:
Ticagrelor is a commercially available antiplatelet adenosine diphosphate ADP antagonists They exert their antiplatelet effects by binding to P2Y12 receptors on the platelet surface Ticagrelor is used in combination with aspirin to prevent and treat thrombosis in patients with acute coronary syndrome particularly after stent implantation
Aspirin has an established role in the treatment of ACS and secondary prevention of ischaemic heart disease Aspirin inhibits cyclo-oxygenase COX enzymes by irreversible acetylation to block platelet aggregation
Evolocumab is a monoclonal antibody targeting proprotein convertase subtilisinkexin type 9 PCSK9 The use of evolocumab significantly reduced the incidence of cardiovascular events compared to statins alone Whether the reduction in cardiovascular events is due to LDL reduction or other mechanisms is currently unclear
Aspirin has an established role in the treatment of ACS and secondary prevention of ischaemic heart disease Aspirin inhibits cyclo-oxygenase COX enzymes by irreversible acetylation to block platelet aggregation
Evolocumab is a monoclonal antibody targeting proprotein convertase subtilisinkexin type 9 PCSK9 The use of evolocumab significantly reduced the incidence of cardiovascular events compared to statins alone Whether the reduction in cardiovascular events is due to LDL reduction or other mechanisms is currently unclear
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None